Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Merck & Company (MRK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 173,465,120
  • Shares Outstanding, K 2,745,570
  • Annual Sales, $ 39,807 M
  • Annual Income, $ 3,920 M
  • 36-Month Beta 0.83
  • Price/Sales 4.36
  • Price/Cash Flow 10.92
  • Price/Book 4.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.86 +0.51%
on 03/24/17
66.80 -5.42%
on 03/01/17
-2.98 (-4.50%)
since 02/24/17
3-Month
58.56 +7.89%
on 12/30/16
66.80 -5.42%
on 03/01/17
+3.62 (+6.08%)
since 12/23/16
52-Week
52.44 +20.48%
on 04/01/16
66.80 -5.42%
on 03/01/17
+10.11 (+19.05%)
since 03/24/16

Most Recent Stories

More News
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval

Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive...

MRK : 63.18 (-0.16%)
KITE : 76.84 (+3.14%)
AMGN : 165.74 (-0.18%)
PFE : 34.00 (-0.85%)
Investors: covered-call reports for Bank of America, The Home Depot Inc., Merck & Company Incorporated, Oclaro Inc. and Square Incorporated.

InvestorsObserver issues critical PriceWatch Alerts for BAC, HD, MRK, OCLR, and SQ.

BAC : 23.12 (+0.22%)
MRK : 63.18 (-0.16%)
HD : 147.71 (-0.19%)
OCLR : 10.11 (+5.64%)
SQ : 16.59 (-0.12%)
European Medicines Agency's CHMP Recommends Approval of Merck's KEYTRUDA(R) (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

MRK : 63.18 (-0.16%)
Merck Manuals Dispels Multiple Sclerosis Myths

Though multiple sclerosis (MS) is one of the most common diseases affecting the central nervous system, misconceptions and outdated stereotypes about the condition persist.

MRK : 63.18 (-0.16%)
Merck Closes Acquisition of Controlling Stake in Vallee S.A

Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.

MRK : 63.18 (-0.16%)
LLY : 84.18 (-0.28%)
ZTS : 53.85 (+0.09%)
SNY : 44.63 (+0.27%)
Merck Animal Health Completes Acquisition of Vallee S.A.

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallee S.A., a leading privately-held...

MRK : 63.18 (-0.16%)
The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA

The Zacks Analyst Blog Highlights: Merck, General Electric, MasterCard and NVIDIA

NVDA : 107.47 (+0.35%)
MA : 111.98 (+0.34%)
MRK : 63.18 (-0.16%)
GE : 29.72 (+0.34%)
ZEPATIER® now covered in Quebec for the treatment of chronic hepatitis C

Merck Canada Inc. today announced that ZEPATIER(® )(elbasvir/grazoprevir) will be listed among the drugs covered by Quebec's health insurance board, the Régie de l'assurance maladie du Québec (RAMQ),...

MRK : 63.18 (-0.16%)
Top Research Reports for Merck, GE and Others

Top Research Reports for Merck, GE and Others

TGT : 53.12 (-0.04%)
PYPL : 43.13 (-0.02%)
NVDA : 107.47 (+0.35%)
MA : 111.98 (+0.34%)
MRK : 63.18 (-0.16%)
SPG : 167.95 (+0.23%)
GE : 29.72 (+0.34%)
Why Biotech Stock Gilead (GILD) Could Be a Value Trap

Gilead's (GILD) valuation looks compelling but is the company really poised for

CELG : 123.38 (+0.13%)
MRK : 63.18 (-0.16%)
GILD : 67.51 (+0.03%)
AMGN : 165.74 (-0.18%)
GSK : 42.31 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines...

See More

Support & Resistance

2nd Resistance Point 63.86
1st Resistance Point 63.52
Last Price 63.18
1st Support Level 62.85
2nd Support Level 62.52

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.